<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Krause-Heuer AM</submitter><funding>NIDA NIH HHS</funding><funding>NIMH NIH HHS</funding><funding>Australian Institute of Nuclear Science and Engineering</funding><funding>National Institutes of Health</funding><funding>United States Department of Defense</funding><funding>NIGMS NIH HHS</funding><pagination>476-487</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5564211</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>137</volume><pubmed_abstract>Herein we describe the synthesis and evaluation of antidepressant properties of seven analogues (1-7) of the low affinity/high capacity transporter blocker decynium-22 (D-22). All analogues (1-7) were synthesized via base promoted coupling reactions between N-alkylated-2-methylquinolinium iodides or N-alkylated-4-methylquinolinium iodides and electrophilic N-alkylated-2-iodoquinolinium iodides. All final compounds were purified by re-crystallization or preparative HPLC and initial evaluation studies included; 1) screening for in vitro α1-adrenoceptor activity (a property that can lead to unwanted side-effects), 2) measuring antidepressant-like activity in a mouse tail suspension test (TST), and 3) measuring effects upon mouse locomotion. The results showed some analogues have lower affinities at α1-adrenoceptors compared to D-22 and showed antidepressant-like activity without the need for co-administration of SSRIs. Additionally, many analogues did not affect mouse locomotion to the same extent as D-22. Plans for additional evaluations of these promising analogues, including measurement of antidepressant-like activity with co-administration of selective serotonin re-uptake inhibitors (SSRIs), are outlined.</pubmed_abstract><journal>European journal of medicinal chemistry</journal><pubmed_title>Evaluation of the antidepressant therapeutic potential of isocyanine and pseudoisocyanine analogues of the organic cation decynium-22.</pubmed_title><pmcid>PMC5564211</pmcid><funding_grant_id>T32 DA031115</funding_grant_id><funding_grant_id>K12 GM111726</funding_grant_id><funding_grant_id>GM097632</funding_grant_id><funding_grant_id>R25 GM097632</funding_grant_id><funding_grant_id>12074</funding_grant_id><funding_grant_id>T32DA031115</funding_grant_id><funding_grant_id>AR110109</funding_grant_id><funding_grant_id>K12GM111726</funding_grant_id><funding_grant_id>MH093320</funding_grant_id><funding_grant_id>R01 MH093320</funding_grant_id><pubmed_authors>Wyatt NA</pubmed_authors><pubmed_authors>Greguric I</pubmed_authors><pubmed_authors>Fraser BH</pubmed_authors><pubmed_authors>Fraser-Spears R</pubmed_authors><pubmed_authors>Dobrowolski JC</pubmed_authors><pubmed_authors>Koek W</pubmed_authors><pubmed_authors>Roberts MP</pubmed_authors><pubmed_authors>Ng CKL</pubmed_authors><pubmed_authors>Kumar N</pubmed_authors><pubmed_authors>Ashford ME</pubmed_authors><pubmed_authors>Bhadbhade M</pubmed_authors><pubmed_authors>Daws LC</pubmed_authors><pubmed_authors>Cheah WC</pubmed_authors><pubmed_authors>Krause-Heuer AM</pubmed_authors><pubmed_authors>Gould GG</pubmed_authors><pubmed_authors>Wheate NJ</pubmed_authors><pubmed_authors>Callaghan PD</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of the antidepressant therapeutic potential of isocyanine and pseudoisocyanine analogues of the organic cation decynium-22.</name><description>Herein we describe the synthesis and evaluation of antidepressant properties of seven analogues (1-7) of the low affinity/high capacity transporter blocker decynium-22 (D-22). All analogues (1-7) were synthesized via base promoted coupling reactions between N-alkylated-2-methylquinolinium iodides or N-alkylated-4-methylquinolinium iodides and electrophilic N-alkylated-2-iodoquinolinium iodides. All final compounds were purified by re-crystallization or preparative HPLC and initial evaluation studies included; 1) screening for in vitro α1-adrenoceptor activity (a property that can lead to unwanted side-effects), 2) measuring antidepressant-like activity in a mouse tail suspension test (TST), and 3) measuring effects upon mouse locomotion. The results showed some analogues have lower affinities at α1-adrenoceptors compared to D-22 and showed antidepressant-like activity without the need for co-administration of SSRIs. Additionally, many analogues did not affect mouse locomotion to the same extent as D-22. Plans for additional evaluations of these promising analogues, including measurement of antidepressant-like activity with co-administration of selective serotonin re-uptake inhibitors (SSRIs), are outlined.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2025-04-26T12:57:23.778Z</modification><creation>2019-03-26T23:54:28Z</creation></dates><accession>S-EPMC5564211</accession><cross_references><pubmed>28624702</pubmed><doi>10.1016/j.ejmech.2017.06.011</doi></cross_references></HashMap>